BSEResult2d ago · 12 Aug 2026, 03:34 pm
Financial Results for the quarter ended on 30-06-2026
Indo Us Bio-Tech Ltd · 541304
✦ AI SummaryResults
Indo Us Bio-Tech Ltd has announced its financial results for the quarter ended June 30, 2026, with a net profit of ₹307.70, up from ₹237.82 in the previous quarter. The company's total comprehensive income is ₹303.74, and its equity share capital is ₹2,005.20. The financial results were approved by the Board of Directors and reviewed by the Statutory Auditors.
Analysis Scores
Earnings Impact6/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Indo Us Bio-Tech Ltd - 541304 - Results- Financial Results For June 30, 2026
Attachments (1)
📄pdf
Download →
800a3b0e-e1f8-431d-bfa7-1966155a8ee6.pdf
View document text
& INDO US A"
BIO-TECH LIMITED
Indo-US (AN ISO CERTIFIED COMPANY)
Agiiieeds CIN LO1122GJ2004PLC043550
Date: 12 August, 2026
BSE Limited National Stock Exchange of India Limited
Dept. of Corporate Services, Dept. of Corporate Compliances,
Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1 Block-G,
Dalal Street, Bandra Kurla Complex,
Mumbai- 400 001 Bandra (E) Mumbai- 400 051
BSE Scrip Code - 541304 NSE Symbol: INDOUS
Sub: Submission of Standalone Unaudited Financial Results of the Company for the quarter
ended June 30, 2026.
Dear Sir,
This is with reference to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015. In this regard, we wish to inform you that the Board of Directors has,
at its meeting held today i.e. on Wednesday, 12 August, 2026 considered and approved the Standalone
Unaudited Financial Results of the Company for the quarter ended June 30, 2026 together with Limited
Review Report of the Statutory Auditors.
The same were also reviewed by the Audit Committee at its meeting held today. A copy of the aforesaid
Unaudited Financial Results along with Limited Review Report is as under.
Pursuant to Regulation 46(2)(I)(ii) of Listing Regulations, the aforesaid financial results are being
uploaded on the website of the Company i.e. https:/indousagriseeds.com/
The above said Meeting commenced at 14:30 P.M. and concluded at 15:10 P.M.
This is for your kind information and record.
Thanking you,
For, Indo us Bio Tech Limited
Digitally signed by DIMPY
DIMPY DIVYANGBHAI DIVYANGBHAI JOSHI
JOSHI Date: 2026.08.1215:14:44
+0530
Ms. Dimpy Joshi
Company Secretary & Compliance officer
o 5 .
E-mail : indous_jagdish{@yahoo.co.in + indo-us_agrisciences:
Wob " www indousaiseocdosm
7i INDO US §
BIO-TECH LIMITED
Indo-US (AN 1SO CERTIFIED COMPANY)
Agriseeds CIN LO1122GJ2004PLC043550 o
T Us Blotech e
oo ans e, Satachar CO hI aN r: HL a0 s1 t1 a2 O2 pG pJ .2 0 N0 a4 wP a( n C go T4 o3 w5 e5 r0 , Sola Road, Abmedabad, Gularat 380081
B¢ o |Particusars Statement of Standalone Unau Bdite d Financial Resuits for
ut ah re iq eu ra r Et ne dr
nded on_June 30, 2026
1 [Refvrome Opnerautioens June 30, 2026 March 31,2026 June 30, 2025 March 31,2026
2 | TO ot th ae lr I i nn cc oom me e 33 ,, 32 10 1 18 2 .. . 06 3 58 8 22 ,6 600 422 .14 65 27 33 ,, 00 77 706 ... 119 156
11,043 91
3 P|uErxcpehnassees :o-f stock in trade
Production Expenses 52419 30837 71514 311691
[( PC rh oga rn eg sse i asn n n d Sv toe ckn it n To rof a r dF ei .in ieshsed Goods, Workin. 862.55 344093 88395 783404 ;
[FEimnpalnocyee Geo Bsetnse fits Expense } 1,2 23e1 65 2. 899 946 (1,9 2460 3 67 0.. 915 3 798 6) ! 8 4 21 35 03 2, .. ,1 002 0 464 (2. 1292 5464 02. 38 212 3 23)| {| |
54 |[ EP xr co ef pi tt i( oL no as ls )
tb ee mf so .r e
r‘ ie ox rc e Pp et ri io on da l
ti et me sm s and tax 3, 302 006 738 ..6 3. 759 0°0 2, 233 369 r64 .. 85 8 26 0 2, 452 808 165 ... 915 929 9 11 , ,, 6 31 5 97 7 23 .
3 06 1 20
|P |r To afi xt
a xf pt ee nr
ee xceptional item before tax
307.70 237.82 481.99
1,392.-
D Te of te alr re Td ax T Ea xx p
eCnh
E aax crp gse
n ses! (Written back) ©3a .2 7r 57s
02 1135 8.81 7523
Ti46 .89 705
s N2a
8 |NetProfit/(Lfoors tsh)ep eriod/year
9 [Other comprehensive income (net of tax) 303.74 19797 47024 1,312.29
tBA o..
(((( ri1ii
o)) )
Il iI tt tnn
ac mm
nsos
dm tt
e hh
a oT att sa
ww sx ii
el n lbn d
ao t ta
ib eb
gv oar a se
sc til efa mis ses di
f hti aoe
wt ioo
r bto eaf .rni et
o fs is
00 .. 00 2)8 ] { 00. .2 09 7)] 0 0. .7 28 0)]
10 |Total Comprehensive Income
- 0.06 ©21) ©.B
11 | |P sa hi ad r- e)u p equity share capital (face value of Rs.10 per 303.74 187.11 47045 1,312.87
|O -DEt BiPh alSe
i t (y
a( cex ec Vl au ldi un eg
r fe Rv sa .l 1u 0a /t -i eon ar ce hs )e
rve)
2,005.20 2,005.20 2,005.20 2 7, .0 20 45 8. .2 10
~Adjusted
11.5511 00.5988 223355
66.5544
Notes *not annualised 1.51 0.98 235 6.54
|t (1 h) e T Ch oe m f pi an nan yc i ha al v r ee s eu xl pt rs ew se sr ee d r ae nv ui ne mw oe dd i b fiy e t dh ‘e o pA iu nd ii ot n C oo nm tm hi et st ee re e sa uln td s. a pproved by the Board of Directors at its meeting held on 12.08.2026 and the Statutory Auditors
(g 4{ ) T;) hv e7h f%‘ ic gwo uem rrp esea n hny ao i v s i e nd b ve eea s el t ni on r rg eci o gn m rpo oln uae pi‘ n etm sa j nor p eP nr do jd ngu , uc It r es ce ag im ve men dt , d ui. re. i nS g ‘e te hd e pCu el rt i mi ov gat ui no dn e, r P y ar ro pc ie es ws .i ng & Trading.
CMARTERED ACCOUNTANTS
For and on behalf of Boargl of Dire tors |
Vi h D Ajudiya)
Piac Managing Director|
DIN: 01745951|
Regd, Office: VXSSTTHSH Y DSIRRECOGNSNIITTIOIN ON IN HOUSE R&D UNIT
, Shanti Mall, Sattadhar Cross Road, Factory A ddre€ ss : s
gopgp N:Vlflng Tower, Ahmedabad-380 061. x‘::rg:::i?amfigg.?r"%:-bengam'
L"é&i"?‘ifié&ffiifiéw" Dist-Gandhinagar, Gujarat,
E-mail : indousexim@gmail.com e Web : www.indousagriseeds.com
BHAGAT & ASSOCIATES
CHARTERED ACCOUNTANTS
oB-1204, SHIoLP CORPORATE P T
CAR. K. BHAGAT BODAKDEV, AHMEDABAD-380054
CA MANISH BHAGAT @({ Q) +9197252 57136, +91 98790 61500
= bhagatasso@gmail.com,
CA SHIKHA BHAGAT
CA SUNIL PATEL | N D I A rkmbhagat@gmail.com
@ https:;//www.bhagatandassociates.org
CA VAIBHAV SHINGALA
INDEPENDENT AUDITOR'S REVIEW REPORT ON THE
QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND-
AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO
REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND
DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED.
LIMITED REVIEW REPORT
The Board of Directors,
Indo US Bio-Tech Limited,
Ahmedabad, Gujarat
1. We have reviewed the accompanying standalone statement of unaudited financial
results of Indo US Bio-Tech Limited (CIN: L01122GJ2004PLC043550) (the
company) for the quarter ended 30th June 2026 ('The Statement') being submitted
by the Company pursuant to the requirements of regulation 33 of the Securities
and Exchange Board of India (Listing Obligation and Disclosure Requirements)
Regulation 2015 as amended (Listing Regulations).
2. This standalone statement which is the responsibility of the Company's
Management and has been approved by the Board of Directors, has been
prepared in accordance with Ind-AS 34 -Interim Financial Reporting'
prescribed under section 133 of the Companies Act. 2013 (the Act) read with
relevant rules issued there under and other recognized accounting practices and
policies generally accepted in India. Our responsibility is to issue a report on these
standalone financial statements based on our review. 0
3. We conducted our review of the standalone Statement in accordance with the
Standard on Review Engagements (SRE) 2410 "Review of Interim Financial
Information Performed by the Independent Auditor of the Entity", issued by the
Institute of Chartered Accountants of India. This standard requires that we plan
and perform the review to obtain moderate assurance as to whether the
standalone financial statements are free of material misstatement. A review of
interim financial information consists of making inquiries, primarily of persons
responsible for financial and accounting matters, and applying analytical and
other review procedures. A review is substantially less in scope than an audit
conducted in accordance with Standards on Auditing and consequently does not
enable us to obtain assurance that we would become aware of all significant
matters that might be identified in an audit. Accordingly, we do not express an
audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that
causes us to believe that the accompanying standalone statement of unaudited
financial results prepared in accordance with applicable accounting standards
specified under Section 133 of the Companies Act, 2013 as amended, read with
relevant rules made thereunder and other accounting principles generally
accepted in India and other recognized accounting practices and policies has not
disclosed the information required to be disclosed in terms of Regulation 33 of the
SEBI (Listing Obligations and
[Showing first 8,000 characters — download PDF for full document]